$PFE Recent News The inscrutable gold timers 10:26 a.m.

New Post Public Reply Private Reply Replies (0) Message Board

Jan 30, 2014 at 1:32 PM

$PFE Recent News

The inscrutable gold timers 10:26 a.m. Today - Mark Hulbert
Updates, advisories and surprises 5:31 p.m. Jan. 28, 2014 - MarketWatch
U.S. stocks rise; Dow breaks 5-day skid 5:02 p.m. Jan. 28, 2014 - Anora Mahmudova
Stocks rebound, helping Dow quit loss streak; Yahoo drops after hours (Stock market live blog recap) 4:31 p.m. Jan. 28, 2014 - blogs.marketwatch.com
Newscast: Stocks back in the win column 4:27 p.m. Jan. 28, 2014 - MarketWatch
Apple sees worst day in a year; Casablanca lifts Cliffs 3:10 p.m. Jan. 28, 2014 - Ben Eisen
Pfizer beats views, even as fourth-quarter sales and earnings slide 12:28 p.m. Jan. 28, 2014 - blogs.marketwatch.com
U.S. stocks rebound on Ford, DuPont; Apple falls 9:37 a.m. Jan. 28, 2014 - Laura Mandaro
Ford shares rise 1%; Pfizer gains 2.6% 9:33 a.m. Jan. 28, 2014 - Laura Mandaro
U.S. stock futures pare gains; Apple weighs on tech 9:19 a.m. Jan. 28, 2014 - Barbara Kollmeyer
Apple's beating, TPDH and America's 'false dawn' recovery 9:17 a.m. Jan. 28, 2014 - blogs.marketwatch.com
Newscast: Fed policymakers gather in Washington 7:30 a.m. Jan. 28, 2014 - MarketWatch
Pfizer profit hurt by generics competition 7:23 a.m. Jan. 28, 2014 - MarketWatch.com
Pfizer shares rise after earnings beat 7:18 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer shares rise 2% premarket 7:10 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer sees 2014 adj. sales of $49.2B to $51.2B 7:09 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer sees 2014 adj. EPS of $2.20 to $2.30 7:08 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer Q4 EPS $0.39; Adj. EPS $0.56 7:07 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer Q4 profit falls 59% to $2.57 billion 7:07 a.m. Jan. 28, 2014 - Saumya Vaishampayan
Pfizer Q4 sales down 2% to $13.56 billion 7:06 a.m. Jan. 28, 2014 - Saumya Vaishampayan

Dassault Systemes Acquires Accelrys 11:17 a.m. Today - TheStreet.com
March 7th Options Now Available For Pfizer (PFE) 10:42 a.m. Today - TheStreet.com
9 New Stock Buybacks to Keep on Your Radar 5:14 a.m. Today - InvestorPlace.com
ACCL Stock – Accelrys Shares Skyrocket on Dassault Deal 3:15 a.m. Today - InvestorPlace.com
Pharma Strength Expected To Continue With Eli Lilly 8:53 p.m. Jan. 29, 2014 - Seeking Alpha
Another Strong Earnings Beat from Amgen - Analyst Blog 11:30 a.m. Jan. 29, 2014 - Zacks.com
Stock Market News for January 29, 2014 - Market News 10:06 a.m. Jan. 29, 2014 - Zacks.com
Top Analyst Upgrades and Downgrades: American Airlines, EA, Teradata, VMware, Walmart and More 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
Pfizer Inc. (PFE): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 29, 2014 - Zacks.com
'Mad Money' Lightning Round: Sell, Sell, Sell Windstream 6:00 a.m. Jan. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Agilent Is Sensational (1/28/14) 5:16 a.m. Jan. 29, 2014 - Seeking Alpha
Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products 3:01 a.m. Jan. 29, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Where Have All the Sellers Gone? 8:34 p.m. Jan. 28, 2014 - TheStreet.com
Bitter Medicine in Store for Activists 8:13 p.m. Jan. 28, 2014 - WSJ.com
Bayer's Aleve May Have Lower Cardiac Risk Than Rival Painkillers 7:20 p.m. Jan. 28, 2014 - WSJ.com
Pfizer's CEO Discusses Q4 2013 Results - Earnings Call Transcript 5:04 p.m. Jan. 28, 2014 - Seeking Alpha
The 4 Stocks That Dominated the Market on Tuesday 4:02 p.m. Jan. 28, 2014 - 247WallSt.com
Pfizer coy about split/spinoff plans 2:44 p.m. Jan. 28, 2014 - Seeking Alpha
Pfizer Upbeat About Breast-Cancer Drug, Pneumonia Vaccine 2:29 p.m. Jan. 28, 2014 - WSJ.com
Pfizer Stock Floats on Financial Engineering, Not Growth 5:39 a.m. Jan. 28, 2014 - InvestorPlace.com

Pfizer Reports Fourth-Quarter and Full-Year 2013 Results;Provides 2014 Financial Guidance 7:01 a.m. Jan. 28, 2014 - BusinessWire - BZX
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Jan. 27, 2014 - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX
Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives 10:09 a.m. Jan. 13, 2014 - ACCESSWIRE
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 8:47 a.m. Jan. 9, 2014 - PR Newswire
Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer's Disease 8:03 a.m. Jan. 9, 2014 - PR Newswire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Nodality Enters into a Strategic Collaboration with Johnson & Johnson Innovation in Autoimmune Diseases 7:59 a.m. Jan. 8, 2014 - BusinessWire
Clinical Studies and Financial Results - Research Report on Pfizer, United Therapeutics, Insys, Puma Biotechnology, and Acorda 8:00 a.m. Jan. 1, 2014 - PR Newswire
Senesco Announces Letter of Intent to Merge with Fabrus 9:38 a.m. Dec. 30, 2013 - BusinessWire
Senesco Announces Letter of Intent to Merge with Fabrus 8:52 a.m. Dec. 30, 2013 - BusinessWire
Regulatory Submissions, New Clinical Trials, Results Scheduled, and Conference Calls - Research Report on Pfizer, Novartis, Teva, Universal Health Services, and BD 8:00 a.m. Dec. 24, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...